Nasal spray for Alzheimer's passes first safety check in small study
NCT ID NCT07187141
First seen Sep 30, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This study tested a nasal spray called Protollin in 16 people aged 60-85 with early Alzheimer's disease. The main goal was to see if it is safe and tolerable, not to cure the disease. Participants received two doses one week apart and were monitored for side effects. The results help researchers understand if this approach is worth further study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.